COVID-19 vaccination hesitancy among patients admitted to the immunology and allergy clinic with drug allergies

Elif Haznedaroglu Benlioglu; Seda Bayrak Durmaz; Göksal Keskin

doi:10.26900/hsq.2056

Authors

Elif Haznedaroglu Benlioglu Ankara University / Türkiye 0000-0001-6142-9001
Seda Bayrak Durmaz Ankara University / Türkiye 0000-0001-8272-5686
Göksal Keskin Ankara University / Türkiye 0000-0001-8553-5378

10.26900/hsq.2056

Abstract

The aim of our study was to determine the factors responsible for COVID-19 vaccination acceptance and hesitancy in patients with drug allergies. We prepared a survey to understand the thoughts, hesitancies and experiences about COVID-19 vaccination and COVID-19 infection in patients with drug allergies and statistically examined the results. A survey study was applied to 76 patients who were admitted to Ankara University Internal Medicine Allergy and Immunology Department with drug allergies. 38 patients who were vaccinated and 38 patients who weren’t were compared. Among the 38 patients who were vaccinated, 34 (89.5%) chose Biontech vaccine, 4 (10.5%) chose Sinovac vaccine. Among the patients who weren’t vaccinated, 28 (73.7%) explained they weren’t vaccinated
because of drug allergies. Educational statuses were statistically significantly different (p=0.026) among vaccinated and non-vaccinated patients, lower in vaccinated patients. Vaccinated patients thought the vaccine reduced the possibility of COVID-19 infection and complications, which was significantly different (p<0.01). Non-vaccinated group significantly feared the possible allergic reaction to the COVID-19 vaccine, more than the vaccinated group (p=0.028). Fear of the possible side effects of the COVID-19 vaccine (p<0.001) and the thought of the COVID-19 vaccine being associated with unpredictable effects were significantly more evident in the non-vaccinated group (p<0.001). In conclusion, our study analyzed multiple factors in drug allergy patients regarding vaccine acceptance, rejection, and hesitancy for the first time in literature, similar studies with larger samples can also contribute to the literature in the future.

Keywords:

COVID-19 COVID-19 vaccines drug Hypersensitivity vaccination hesitancy

Downloads

Download data is not yet available.

References

WHO. WHO Coronavirus (COVID-19) Dashboard. Retrieved from https://covid19.who.int/

COVID19 Vaccine Tracker. Retrieved from https://covid19.trackvaccines.org/vaccines/

WHO. Ten threats to global health in 2019. Retrieved from https://www.who.int/news-room/ spotlight/ten-threats-to-global-health-in-2019

Solis Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low- and middleincome countries. Nat Med. 2021;27(8):1385-94. doi: 10.1038/s41591-021-01454-y.

Majid U, Ahmad M, Zain S, Akande A, Ikhlaq F. COVID-19 vaccine hesitancy and acceptance: a comprehensive scoping review of global literature. Health Promot Int. 2022;37(3):1-12. doi:10.1093/heapro/daac078.

Abrams EM, Shaker M, Sinha I, Greenhawt M. COVID-19 vaccines: addressing hesitancy in young people with allergies. Lancet Respir Med. 2021;9(10):1090-2. doi: 10.1016/S2213-2600(21)00370-2.

Klass P, Ratner AJ. Vaccinating children against Covid-19 - the lessons of measles. N Engl J Med. 2021;384(7):589-91. doi: 10.1056/NEJMp2034765.

Glover RE, Urquhart R, Lukawska J, Blumenthal KG. Vaccinating against covid-19 in people who report allergies. BMJ. 2021;372:n120. doi: 10.1136/bmj.n120.

Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-67. doi: 10.1016/j.jaip.2021.06.006.

Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020;38(49):7789-98. doi: 10.1016/j.vaccine.2020.10.027.

Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA Covid-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2. doi: 10.1001/jama.2021.1967.

Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to Covid-19 vaccines. Allergy. 2021;76(6):1629-39. doi: 10.1111/all.14739.

Sarasty O, Carpio CE, Hudson D, GuerreroOchoa PA, Borja I. The demand for a Covid-19 vaccine in Ecuador. Vaccine. 2020;38(51):8090-8. doi: 10.1016/j.vaccine.2020.11.013.

Khairat S, Zou B, Adler-Milstein J. Factors and reasons associated with low Covid-19 vaccine uptake among highly hesitant communities in the US. Am J Infect Control. 2022;50(3):262-7. doi: 10.1016/j.ajic.2021.12.013.

Kucukali H, Atac O, Palteki AS, Tokac AZ, Hayran O. Vaccine hesitancy and anti-vaccination attitudes during the start of COVID-19 vaccination program: a content analysis on twitter data. Vaccines (Basel). 2022;10(2):161. doi: 10.3390/vaccines10020161.

Cascini F, Pantovic A, Al-Ajlouni YA, Failla G, Puleo V, Melnyk A, et al. Social media and attitudes towards a Covid-19 vaccination: a systematic review of the literature. EClinicalMedicine. 2022;48:101454. doi: 10.1016/j.eclinm.2022.101454.

Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. Covid-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med. 2020;1-15. doi: 10.1017/S0033291720005188.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind,placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181-92. doi: 10.1016/S1473-3099(20)30843-4.

Dighriri IM, Alhusayni KM, Mobarki AY, Aljerary IS, Alqurashi KA, Aljuaid FA, et al. Pfizer-BioNTech Covid-19 vaccine (BNT162b2) side effects: a systematic review. Cureus. 2022;14(3):e23526. doi: 10.7759/cureus.23526.

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21:39-51. doi: 10.1016/S1473-3099(20)30831-8.

Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398:213-22. doi: 10.1016/S0140-6736(21)01429-X.

Evren H, Evren EU, Baris SA, Ince FG, Soydan C, Elci OC, et al. Comparison of adverse effects of Covid-19 vaccines among elderly: Pfizer/BioNTech versus CoronaVac. Acıbadem Univ Sağlık Bilim Derg. 2023;14(3):353-9. doi: 10.31067/acusaglik.1076933.